Form 4 for TNXP Tonix Pharmaceuticals Holding Corp.
Accepted 2026-06-09 17:30:02 ET · period of report 2026-06-09 · accession 0001493152-26-027986 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-09 17:30 | 2026-06-09 | TNXP | LEDERMAN SETH | CEO, Dir | P - Purchase | $11.79 | +5,000 | 9,005 | +125% | +$58.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.001 par value | 2026-06-09 | P | A | 5,000 | $11.79 | 9,005 | D | — | — | (F1) Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $11.735 to $11.883 per share. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. |